Broad Institute Co-Founder Eric Lander on Decoding Life and Clean Energy

Eric Lander, co-founder of the Broad Institute, discusses his pioneering work in genomics, the founding of Harvard and MIT's joint research center, his tenure in Washington, and his new clean energy startup, Pacific Fusion.

Broad Institute Co-Founder Eric Lander on Decoding Life and Clean Energy
Photo: Unsplash / National Cancer Institute

Eric Lander, mathematician, biologist, and co-founder of the Broad Institute of Harvard and MIT, reflects on decades of groundbreaking scientific initiatives, his time in Washington, and his newest venture in clean energy. In the early 2000s, following the successful mapping of the Human Genome Project, Lander faced the challenge of translating scientific discovery into practical medical value.

Building the Broad Institute Across Rival Universities

Philanthropists Eli and Edythe Broad offered an initial $100 million contribution to establish a research institute, conditional upon an unprecedented collaboration between academic rivals: Harvard University and the Massachusetts Institute of Technology. Lander utilized venture capital tactics such as the soft circling strategy to convince both institutions that the other was already on board.

Lander noted that timing played a crucial role in securing institutional buy-in. When consulting leadership, the transition points of academic presidencies offered a unique window for visionary projects. The Broad Institute eventually secured more than $2 billion from various donors, evolving into a premier global research institution uniting Harvard, MIT, and leading Boston hospitals.

Decoding the Human Genome to Transform Medicine

Modern genomics requires understanding the subtle differences between millions of genomes, cellular interactions, and how identical genes behave differently across diverse cell types or cancerous tissue. At the Broad Institute, researchers are cataloging human cell activity and mapping mechanisms that fail in cancer.

These mega-projects have yielded significant clinical advancements, including twenty drugs currently in clinical trials, an approved lung cancer treatment, and diagnostic tests for residual cancer cells. Lander envisions a periodic table of biology that will enable researchers to read and write the code of life with unprecedented precision.

Breakthroughs in Genetic Diseases and Aging Research

Addressing complex conditions like sickle cell anaemia involves targeted genetic intervention. Researchers successfully mapped the gene that represses fetal hemoglobin production and used CRISPR gene-editing technology to achieve full therapeutic recovery, with the treatment receiving regulatory approval in 2023.

Alzheimer's disease presents a more intricate challenge due to multi-gene interactions within microglia cells in the brain. Lander estimates that comprehensive genomic mapping will unlock precise targeted treatments for complex neurological conditions within the next two to three decades.

Washington Service and the Pacific Fusion Venture

Lander served as the senior science advisor to former US President Joe Biden, contributing to classified security initiatives, cancer research funding, and pandemic preparedness planning before stepping down in 2022. Following his government tenure, he co-founded Pacific Fusion to tackle the global energy crisis through low-cost, clean fusion power.

The clean energy company leverages a unique approach to magnetic field generation using pulsed electrical currents. Pacific Fusion has successfully satisfied 16 out of 18 technical milestones and aims to demonstrate its functional prototype by 2030, with artificial intelligence accelerating research across both biological and physical sciences.

Related News